Article
A multidisciplinary approach for the identification of novel HIV-1 non-nucleoside reverse transcriptase inhibitors: S-DABOCs and DAVPs.
ChemMedChem - 1 Apr 2008
Radi Marco, Falciani Chiara, Contemori Lorenzo, Petricci Elena, Maga Giovanni, Samuele Alberta, Zanoli Samantha, Terrazas Montserrat, Castria Marinunzia, Togninelli Andrea, Esté José A, Clotet-Codina Imma, Armand-Ugón Mercedes, Botta Maurizio
Abstract excerpt
Among the FDA approved drugs for the treatment of AIDS, non-nucleoside reverse transcriptase inhibitors (NNRTIs) are essential components of first-line anti-HIV-1 therapy because of the less-severe adverse effects associated with NNRTIs administration in comparison to therapies based on other anti-HIV-1 agents. In this contest, 3,4-dihydro-2-alkoxy-6-benzyl-4-oxypyrimidines (DABOs) have been the object of many...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
